Working… Menu

VR-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02427997
Recruitment Status : Unknown
Verified March 2019 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Recruiting
First Posted : April 28, 2015
Last Update Posted : March 26, 2019
Information provided by (Responsible Party):
Tel-Aviv Sourasky Medical Center

Brief Summary:
A prospective, randomized controlled single-blind trial will test the hypotheses that a 6- week intervention that combines treadmill training (TT) with virtual reality (VR) significantly improves real-life, functional mobility and cognitive abilities, keys to health-related quality of life in patients with MS.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Behavioral: Treadmill training with Virtual Reality Behavioral: Treadmill training Not Applicable

Detailed Description:
A prospective, single blinded,randomized controlled trial with 6 month follow-up will be employed to investigate the effects of treadmill training augmented with virtual reality on patients with MS. The study will include 200 participants. Participants will be randomized to either the intervention or active comparator. The intervention group will receive 18 sessions of Treadmill Training with Virtual Reality (TT+VR) and the active control comparison will receive 18 training sessions of treadmill training alone (TT) without the VR simulation All interventions will be delivered by therapists trained in the standard protocols. All subjects will be trained 3 times a week for 6 weeks, each session will last approximately 45 minutes.Training progression will be based on increasing both motor and cognitive challenges, individualized to the participant's level of performance.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Virtual Reality-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis
Actual Study Start Date : June 2015
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treadmill training with virtual reality
The TT+VR patients (i.e., the experimental arm) will receive 18 sessions (3 times per week x 6 weeks) of training that will consist of walking on a treadmill while wearing a safety harness (without body weight support, recall Figure 1), and while being provided with feedback from the system.
Behavioral: Treadmill training with Virtual Reality
VR is defined in general as a "high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels". The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components.
Other Name: TT+VR

Active Comparator: Treadmill training alone
TT alone will receive conventional treadmill training with no feedback from the system. They will train with a safety harness 18 sessions (3 times per week x 6 weeks).
Behavioral: Treadmill training
The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
Other Name: TT

Primary Outcome Measures :
  1. Immediate change in gait speed [ Time Frame: One week post intervention ]
    Gait speed will be assessed under usual and dual task conditions and while negotiating physical obstacles, using a sensorized 7 meter carpet (PKMAS) and wearable body fixed sensors. These measures will be compared to baseline performance

  2. Number of correct answers in the oral version of the Symbol Digit Modalities Test [ Time Frame: One week post intervention ]
    The SDMT measures sustained attention and cognitive processing speed, is responsive to change and intervention in MS, can be administered in a relatively short period of time (< 5 minutes), is largely resistant to practice effects, is valid and reliable in MS, and has been used in many clinical trials in MS. The SDMT involves matching numbers to corresponding symbols for 90 seconds and is a main component of the brief international cognitive assessment for MS (BICAMS). The number of correctly matched symbols is considered the outcome score. This test measures attention and visual spatial processing, and it is likely that the SDMT will change in response to the TT+VR, and not in response to TT. Indeed, SDMT has been associated with cognitive motor interference in patients with MS.

Secondary Outcome Measures :
  1. The 25 feet walk test (25FWT) [ Time Frame: One week post intervention ]
    The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk. It is the first component of the MSFC to be administered at each visit. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients will be included if:

  • They are between 18-65 years of age.
  • They have a confirmed diagnosis of relapsing remitting MS.
  • They have a score between 2 and 6 on the Expanded Disability Status Scale (EDSS)
  • They are free from dementia as determined using the Mini Mental State Exam (MMSE>=24)
  • They can walk on the treadmill without partial body weight support harness for 5 minutes at their preferred walking speed; this is set as the smallest bout length at the start of training.
  • They have no history of epileptic seizures.
  • They have no MS exacerbation within the preceding 4 weeks, as determined by interview and medical notes review.
  • They have stable MS disease treatments (e.g., last intake of steroids occurred at least 50 days before the enrolment, MS-specific drugs stable from at least 3 months, symptomatic drugs stable from at least 1 month before the enrolment).
  • They have adequate hearing (as evaluated by the whisper test and adequate vision capabilities (as measured using a Snellen chart, 6.20 cut-off).
  • They are willing to commit to treadmill training program week and participate in all of the assessments.
  • They provide informed written consent and are willing to be randomized to any of the 2 study arms.

Exclusion Criteria:

  • Patients will be excluded if:

    • They cannot follow safety or training instructions.
    • They have another neurological disorder, unstable cardiovascular disease, diabetes, lower limb arthritis, acute lower back or lower extremity pain, peripheral neuropathy, rheumatic or severe orthopaedic problems that may interfere with walking, or have diagnosed psychiatric problems.
    • They are pregnant.
    • They are undergoing any experimental drug or other kind of therapy.
    • Their medication regime is likely to change during the course of the study.
    • They are already participating in an intensive exercise program. The use of walking aids will not exclude participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02427997

Layout table for location contacts
Contact: Anat Mirelman, PhD +972-3-6973960

Layout table for location information
United States, Illinois
Motor Control Research Lab at the University of Illinois Urbana-Champaign Recruiting
Urbana, Illinois, United States, 61801
Contact: Emily Pike    217-244-7006   
Tel Aviv Sourasky Medical Center Recruiting
Tel Aviv, Israel, 6423906
Contact: Shirley Shema, MSPT    +972-3-6947514   
Contact: Marina Brozgol, MSc    +972-3-6947513   
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Layout table for investigator information
Principal Investigator: Arnon Karni, MD TASMC
Layout table for additonal information
Responsible Party: Tel-Aviv Sourasky Medical Center Identifier: NCT02427997    
Other Study ID Numbers: TASMC-15-NG-063-CTIL
First Posted: April 28, 2015    Key Record Dates
Last Update Posted: March 26, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tel-Aviv Sourasky Medical Center:
Virtual Reality
Multiple Sclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases